![Josefin-Beate Holz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Josefin-Beate Holz
Keine laufenden Positionen mehr
Karriereverlauf von Josefin-Beate Holz
Ehemalige bekannte Positionen von Josefin-Beate Holz
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ABLYNX | Technik-/Wissenschafts-/F&E-Leiter | 27.05.2009 | 30.06.2013 |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Corporate Officer/Principal | - | - |
Ausbildung von Josefin-Beate Holz
Philipps University of Marburg | Doctorate Degree |
Statistik
International
Deutschland | 3 |
Belgien | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 2 |
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Ablynx NV
![]() Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
- Börse
- Insiders
- Josefin-Beate Holz
- Erfahrung